Article | October 15, 2026

Why Controlled Release Is Becoming Essential For Patient-Centric Drug Development

drug-development-patient-centric-GettyImages-130405474

Treatment only works if patients can stay on the regimen, which makes formulation a question of adherence. For small molecule oral solid dose programs, controlled release can flatten the peaks and troughs of immediate-release exposure.

The right mechanism depends on the API: diffusion-controlled matrices, osmotic technologies, and biodegradable polymer systems each have to be matched to solubility, permeability, stability, and pharmacokinetic profile. Paediatric, geriatric, and chronic-illness patients each push design in different directions. Manufacturability and scale-up then decide what reaches commercial supply.

Read how the release mechanism is matched to the API.

Access The Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma